about
Elimination of Mother-To-Child Transmission of HIV Infection: The Drug Resource Enhancement against AIDS and Malnutrition ModelMaternal antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Malawi: maternal and infant outcomes two years after deliveryImproving HIV-2 detection by a combination of serological and nucleic acid amplification test assays.Immunologic response to highly active antiretroviral therapy and mortality reduction in a cohort of human immunodeficiency virus-positive persons in Mozambique.Viral sequence analysis of HIV-positive women and their infected children: insight on the timing of infection and on the transmission network.The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi.Nutritional rehabilitation of HIV-exposed infants in Malawi: results from the drug resources enhancement against AIDS and malnutrition programAn assessment of option B implementation for the prevention of mother to child transmission in Dschang, Cameroon: results from the DREAM (Drug Resource Enhancement against AIDS and Malnutrition) cohort.Cost-Effectiveness and Quality of Care of a Comprehensive ART Program in Malawi.Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes.Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi.Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi.Limited risk of drug resistance after discontinuation of antiretroviral prophylaxis for the prevention of breastfeeding transmission of HIV.Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability.Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa.Impact of Extended Combination Antiretroviral Therapy on the Decline of HIV Prevalence in Pregnant Women in Malawi.Predictors of adverse outcomes in HIV-1-infected children receiving combination antiretroviral treatment: results from a DREAM cohort in sub-Saharan Africa.Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-saharan Africa with maternal use of highly active antiretroviral therapy during breast-feeding.Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV.Trend and determinants of acute inpatient care for the elderly in Italy from 2001 to 2011.Assessment of frailty in community-dwelling older adults residents in the Lazio region (Italy): A model to plan regional community-based services.Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi.A pharmacogenetics study in Mozambican patients treated with nevirapine: full resequencing of TRAF3IP2 gene shows a novel association with SJS/TEN susceptibilityCMV infection in a cohort of HIV-exposed infants born to mothers receiving antiretroviral therapy during pregnancy and breastfeeding.Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi.Measurement of viral load by the automated Abbott real-time HIV-1 assay using dried blood spots collected and processed in Malawi and Mozambique.Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants.Comparison of the Cepheid GeneXpert and Abbott M2000 HIV-1 real time molecular assays for monitoring HIV-1 viral load and detecting HIV-1 infection.Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children.Retention, transfer out and loss to follow-up two years after delivery in a cohort of HIV+ pregnant women in Malawi.Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding.Extended antenatal antiretroviral use correlates with improved infant outcomes throughout the first year of life.Weight changes during and after 6 months of breastfeeding in HIV-infected mothers receiving antiretroviral therapy in Malawi.Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.Easier said than done: World Health Organization recommendations for prevention of mother-to-child transmission of HIV-areas of concern.Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings.Evaluating adherence to highly active antiretroviral therapy with use of pill counts and viral load measurement in the drug resources enhancement against AIDS and malnutrition program in Mozambique.Improving adherence to highly active anti-retroviral therapy in Africa: the DREAM programme in Mozambique.ABCC10 rs2125739 polymorphism and nevirapine-induced hepatotoxicity: lack of association in a population from Mozambique.
P50
Q26778483-626DF5CF-1378-41AC-B3A5-C06473D81B0EQ28534751-5D5675C5-0CFD-455D-AEF0-E15D795BDB16Q34046466-22A1CC4A-C733-4BE0-BBDC-A90E6A248788Q34240160-4A9BC7A0-7441-4778-BF13-D4AC862AA5EEQ34266269-FF2C729C-8051-4180-ADD2-372BEFA1E907Q34523530-B96BCDA9-0297-493E-B0B4-E5B1C880A182Q35860439-F6627323-B25E-4137-8914-3D5C1EC395D6Q36888760-6441F9D2-8D07-44A2-B80D-26A45817B6EDQ36992861-75736860-E55E-4E5E-AF73-32E44157FF39Q37889592-E781CF37-3E5A-4F03-B347-4B212EFF45A4Q38385724-7F665E0B-F9CC-4D25-BBCE-CE8EFEACBD56Q38394525-28615BCA-1C72-44E2-93C2-A195453190FBQ38410459-D6FE6BA0-632B-43A6-AC0C-8A551CCEBF0BQ38452483-8A0891E1-2431-47FB-A95C-98321A866F4CQ38966133-4151137A-9A60-4728-8A3F-FE6657C11C06Q39182497-4B7C6991-7468-46CD-83D6-2FB8425229BCQ39213753-E8E56B8E-F0C2-45C9-A8E2-8702A6780319Q39213760-7F054010-4BEB-461A-A9F6-A185E93AE790Q39335189-0275508B-BF89-4300-BD9C-AAAC1423F059Q39391087-22181A3F-C9C6-46CD-B0BC-9A14651AE30EQ39447619-82A56615-2E84-444F-B4CC-DFB94B909578Q39520236-F7B1CCBE-7E4B-470C-A7E5-B0F8EDF2ED56Q39555733-6F7D07A6-82AD-4EA6-945F-74D2B7C7F93BQ40540194-BB0DF3DF-1EE3-4473-BFF9-74AAC90423E4Q40719420-0034C5AC-2570-4F15-916E-74485F5DEAADQ40824339-2B615079-37A3-4793-A21D-8FA27236EE16Q40833730-7938566F-3549-4C38-8E2D-F6C0115FF529Q40855575-2CE0E736-19B2-4836-91BD-360416C3A693Q40867191-5E51D34F-1DD5-4FD0-AEEB-7FDA23DC06C3Q40894200-E9871AE8-DDC6-4759-88F5-A3A7431521C9Q40962161-7957127D-8A2F-429E-9015-B712B7EE9D4CQ41760045-E1302525-171A-4A53-BB1A-173B83FA99DAQ42872394-6D80224A-9887-49DA-9ED2-30E18BF23A52Q43049052-F65AEF33-5735-4233-BB30-54523D8F5335Q43217465-F1F373C7-D1E2-41C5-9FD2-8467C43BE9A1Q43482078-CF8414F1-EF48-4B74-AD01-63069AFEBCFDQ43649738-655C20E8-7779-4491-A502-691E9FB5E7B9Q43811493-F73F1890-12C7-4523-8148-5E5C037D8DB2Q44237932-5B84FB2C-AC57-4443-934C-888ACB02A586Q44444294-1BDA9F7D-B5DC-4E15-A67E-C3C4CFA81F82
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Maria Cristina Marazzi
@ast
Maria Cristina Marazzi
@en
Maria Cristina Marazzi
@es
Maria Cristina Marazzi
@nl
type
label
Maria Cristina Marazzi
@ast
Maria Cristina Marazzi
@en
Maria Cristina Marazzi
@es
Maria Cristina Marazzi
@nl
prefLabel
Maria Cristina Marazzi
@ast
Maria Cristina Marazzi
@en
Maria Cristina Marazzi
@es
Maria Cristina Marazzi
@nl
P106
P1153
7006227365
P21
P31
P496
0000-0003-2031-5213